My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Amgen (NQ:AMGN)

336.74 +0.74 (+0.22%)

Streaming Delayed Price Updated: 4:00 PM EST, Nov 14, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Amgen

< Previous 1 2

...

10 11 12 13 14 15 16 17 18

...

60 61 Next >

Why Amgen's Weight Loss Result Is a Win for Eli Lilly ↗

November 27, 2024

Via The Motley Fool

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

November 26, 2024

Via Benzinga

Stocks Mixed Ahead Of Fed Minutes, Mexican Peso Tumbles To Over 2-Year Lows On Tariffs Fears: What's Driving Markets Tuesday? ↗

November 26, 2024

The U.S. stock market traded mixed on Tuesday morning, with major indices showing tight movements as investors awaited the release of the Federal Reserve's November meeting minutes.

Via Benzinga

Topics Economy

Biden Proposes Medicare, Medicaid Access For Popular Weight-Loss Drugs ↗

November 26, 2024

The Biden Administration's proposal expands Medicare and Medicaid coverage for anti-obesity drugs, cutting costs for millions while addressing the obesity crisis.

Via Benzinga

Decoding Amgen's Options Activity: What's the Big Picture? ↗

November 20, 2024

Via Benzinga

Amgen's Options Frenzy: What You Need to Know ↗

November 14, 2024

Via Benzinga

Pain In Retail ↗

November 26, 2024

It’s been a relatively busy morning for earnings, especially from retailers. Of the ten companies reporting, six topped EPS forecasts, seven beat sales forecasts, but two, Best Buy and Kohl’s lowered...

Via Talk Markets

Topics Stocks / Equities

Amgen Crashes 12% After Weight-Loss Drug Meets Eli Lilly's In A Key Test ↗

November 26, 2024

Over the course of a year, Amgen's MariTide helped patients lose about 20% of their body weight.

Via Investor's Business Daily

Amgen Reveals Data From Closely Watched Monthly Obesity Drug, With Weight Loss Of Up To 20% At One Year And No Plateau ↗

November 26, 2024

Amgen's Phase 2 MariTide trial showed ~20% weight loss at 52 weeks, cardiometabolic improvements, and no significant safety issues.

Via Benzinga

Investing in Pharma Stocks? Check These 3 Things First ↗

November 22, 2024

Via The Motley Fool

Weight-Loss Drugs Don't Seem To Impress RFK Jr. Should Eli Lilly, Novo Nordisk Investors Worry? ↗

November 22, 2024

Robert F. Kennedy hasn't overtly commented on how he would handle GLP-1 drugs. But there are hints.

Via Investor's Business Daily

What Analysts Are Saying About Amgen Stock ↗

November 14, 2024

Via Benzinga

3 Healthcare Stocks For Long-Term Growth And Dividends ↗

November 07, 2024

Healthcare stocks will profit from the U.S. aging population and pay rising dividends over time.

Via Talk Markets

Eli Lilly Stock Tumbles As Kennedy Targets Weight Loss Drugs ↗

November 21, 2024

LLY stock struggles, falling 16.85% over the last month due to bearish technicals and political uncertainty. But with projected sales and earnings growth, could this be a buying opportunity?

Via Benzinga

Silence Therapeutics' Zerlasiran Has Competitive Concerns: Analyst ↗

November 19, 2024

Silence Therapeutics' Phase 2 data shows zerlasiran achieves over 80% Lp(a) reduction in ASCVD patients but faces dosing frequency challenges.

Via Benzinga

Neurogene, Nvidia And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗

November 18, 2024

Via Benzinga

Dow Tumbles Over 300 Points Following Economic Reports, Nvidia, Microsoft Decline: Fear & Greed Index Moves To 'Neutral' Zone ↗

November 18, 2024

Via Benzinga

Topics Stocks

2 Reasons to Buy Amgen Stock, and 1 Reason to Be Cautious ↗

November 16, 2024

Its future is bright, but that doesn't mean it'll always be smooth sailing.

Via The Motley Fool

AMGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Amgen Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

November 15, 2024

From Bragar Eagel & Squire

Via GlobeNewswire

Want Decades of Passive Income? Buy This Index Fund and Hold It Forever ↗

November 15, 2024

This fund could be the perfect investment for those wanting financial freedom through endlessly growing dividends.

Via The Motley Fool

2 Dividend Stocks to Buy Hand Over Fist in November ↗

November 14, 2024

These companies have solid businesses and excellent dividend growth track records.

Via The Motley Fool

Amgen Defends Its Investigational Monthly Weight Loss Injection After Analyst Cites MariTide's Impact on Bone Density ↗

November 13, 2024

Amgen addresses safety concerns for its weight loss drug MariTide after new data suggests a potential 4% reduction in bone density at the highest dose.

Via Benzinga

10 Health Care Stocks With Whale Alerts In Today's Session ↗

November 13, 2024

Via Benzinga

Amgen Rebounds, Shaking Off 'Overdone' Fears Tied To Its Weight-Loss Shot ↗

November 13, 2024

Shares were rattled Tuesday after a report showed its obesity treatment can cause lower bone mineral density.

Via Investor's Business Daily

Jim Cramer Says Eli Lilly's 'Pathetic' Stock Performance Could Get A Breather If Amgen Has Hidden Bone Risk Data After 7% Stock Drop ↗

November 12, 2024

Amgen Inc.'s stock dropped over 7% on Tuesday following revelations about bone density loss in early trials of its experimental obesity drug MariTide, while CNBC's Jim Cramer suggested the news could...

Via Benzinga

Amgen Drops 7% After A 'Big Unknown Risk' Rattles Its Monthly Obesity Shot ↗

November 12, 2024

The company is testing MariTide as a monthly shot, rivaling weekly injections from Novo Nordisk and Eli Lilly.

Via Investor's Business Daily

10 Health Care Stocks Whale Activity In Today's Session ↗

November 12, 2024

Via Benzinga

Don’t Confuse Brains With A Bull Market, Or Price With Value ↗

November 10, 2024

If you are interested in the stock market, maybe it is time to stop focusing on The Fed.

Via Talk Markets

Investors Like Certainty. Trump's Win Gave Them Some. ↗

November 08, 2024

We're also talking about Super Micro, Nvidia, and weight loss.

Via The Motley Fool

Topics Government

AstraZeneca/Amgen's Asthma Drug Aces Late-Stage Study In Patients With Chronic Rhinosinusitis ↗

November 08, 2024

AstraZeneca and Amgen's Phase 3 trial data shows Tezspire significantly reduces nasal polyps and congestion in patients with chronic rhinosinusitis with nasal polyps.

Via Benzinga

< Previous 1 2

...

10 11 12 13 14 15 16 17 18

...

60 61 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.